

Freedom of Information Request	FOI 21-052	24 th February 2021
--------------------------------	------------	--------------------------------

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

- **Aubagio (teriflunomide)**
- **Avonex (interferon beta-1a)**
- **Betaferon (interferon beta-1b)**
- **Brabio (glatiramer acetate)**
- **Copaxone (glatiramer acetate)**
- **Extavia (beta interferon-1b)**
- **Fampyra (fampridine)**
- **Gilenya (fingolimod)**
- **Lemtrada (alemtuzumab)**
- **Mavenclad (cladribine)**
- **Mayzent (siponimod)**
- **Ocrevus (ocrelizumab)**
- **Plegridy (peginterferon beta-1a)**
- **Rebif (beta interferon-1a)**
- **Tecfidera (dimethyl fumarate)**
- **Tysabri (natalizumab)**
- **Zeposia (ozanimod)**

APPROVED NAME	DOSE FORM	STRENGTH	UNIT OF ISSUE	QUANTITY ISSUED
OCRELIZUMAB	CONCENTRATE FOR INFUSION	300mg in 10ml	1 X 10ml	112
DIMETHYL-FUMARATE	ENTERIC COATED CAPSULE	120mg	14 TECFIDERA	2
DIMETHYL-FUMARATE	ENTERIC COATED CAPSULE	240mg	56 TECFIDERA	526
NATALIZUMAB	CONCENTRATE FOR I.V. INFUSION	20mg in 1ml	1 VIAL	155
FINGOLIMOD HYDROCHLORIDE	CAPSULE	500 microgram	28 GILENYA	208
TERIFLUNOMIDE	TABLET	14mg	28 AUBAGIO	114
CLADRIBINE	TABLET	10mg	1 X 6 TABLETS	2
PEGINTERFERON BETA-1a (PLEGRIDY)	PRE-FILLED SYRINGE	125microgram s in 0.5ml	1 PLEGRIDY	52
FAMPRIDINE	PROLONGED RELEASE TABLET	10mg	28 FAMPYRA	50

2. How many patients have been treated in the past 6 months for the following conditions:

- **Multiple Sclerosis (any type)**
- **Relapsing remitting multiple sclerosis (RRMS)**
- **Secondary progressive multiple sclerosis (SPMS)**
- **Primary progressive multiple sclerosis (PPMS)**

The Health Board does not hold this information.